Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature.
Lymphomas rarely develop during pregnancy, but hepatosplenic gammadelta T-cell lymphoma (HSgammadeltaTCL) is extremely rare. We encountered a case of T-cell intracellular antigen-1 (TIA-1) positive and granzyme B-positive HSgammadeltaTCL that developed early during the course of pregnancy. The patient was a 31-yr-old female who was referred to our hospital because of pancytopenia and splenomegaly at the time of the14th week of her gestation. Her pancytopenia and hepatosplenomegaly worsened and she became fibril at the 27th week of gestation and Cesarean section was performed at the 29th week. Histopathological examination of the spleen, which was resected 28 d after delivery for a diagnostic purpose, revealed medium to large-sized nodules composed of dense proliferation of lymphoid cells having round to oval-shaped nuclei and abundant weakly eosinophilic cytoplasm. They were CD3epsilon+, mCD3+, CD4-, CD8-, CD56+, CD79a-, T-cell receptor (TCR)-gammadelta protein+, TIA-1+, and granzyme B+ by either immunohistochemistry or flow cytometry. Clonal rearrangement of TCR-gamma genes without such rearrangement of TCR-delta and TCR-beta genes was confirmed by Southern blot hybridization. Thus, the patient was diagnosed as having HSgammadeltaTCL, and combination chemotherapy was initiated. She is currently in partial remission. To our knowledge, this is the first case report of HSgammadeltaTCL that developed during pregnancy. Pathogenesis of pregnancy-associated lymphoma is not known, but it is possible that maternal immunity during pregnancy or a hormonal imbalance, such as a change in the progesterone level, induces the development of lymphoma. Pregnancy-associated lymphoma is resistant to standard chemotherapy and is associated with poor prognosis. Therefore, it is important to accumulate clinicopathologic data of such cases for the development of a treatment modality.
Niitsu
Nozomi
N
Department of Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan. nniitsu@med.kaisato-u.ac.jp
Kohri
Mika
M
Togano
Tomiteru
T
Nakamine
Hirokazu
H
Nakamura
Shigeo
S
Iwabuchi
Kei-ichi
K
Higashihara
Masaaki
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002585:Cesarean Section; D005260:Female; D005865:Gestational Age; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D008113:Liver Neoplasms / Q000175:diagnosis*; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D010198:Pancytopenia; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D012074:Remission Induction; D013154:Spleen / Q000737:chemistry / Q000473:pathology / Q000601:surgery; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000175:diagnosis*
D016692:Receptors, Antigen, T-Cell, gamma-delta